Financings in Brief: Matritech
This article was originally published in The Gray Sheet
Executive Summary
Matritech: Nets approximately $6.6 mil. from private placement of 3 mil. shares of common stock at $2.30 per share. Proceeds will be used "to fund ongoing in vitro diagnostic development, therapeutic research, marketing of the company's NMP-22 bladder cancer test kit, working capital and general corporate expenses"...